Positive allosteric modulator selective for adult muscle nicotinic acetylcholine receptor

R Richard G. Webster (Nuffield Department of Clinical Neurosciences, University of Oxford) S Setareh Alabaf (Nuffield Department of Clinical Neurosciences, University of Oxford) A Anna Li (Nuffield Department of Clinical Neurosciences, University of Oxford) R Rene Beerli (Novartis Biomedical Research) S Sandra Siehler (Novartis Biomedical Research) P Pierre-Eloi Imbert (Novartis Biomedical Research) L Leonard Lee (Nuffield Department of Clinical Neurosciences, University of Oxford) J Judith Cossins (Nuffield Department of Clinical Neurosciences, University of Oxford) M Magdalena Koziczak-Holbro (Novartis Biomedical Research) L Ludivine Flotte (Novartis Biomedical Research) L Laurent Gaudet (Novartis Biomedical Research) N Nicole Gerwin (Novartis Biomedical Research) D David Beeson (Nuffield Department of Clinical Neurosciences, University of Oxford) Y Yin Y. Dong

Abstract

The muscle nicotinic acetylcholine receptor (AChR) is the key mediator of neuromuscular signal transmission and is essential for all voluntary movement in our body. In this study, we present DC-98-LC74, a positive allosteric modulator (PAM) for the adult skeletal muscle-type AChR. Through using Ca 2+ fluorometric imaging plate reader (FLIPR) assays, we demonstrate that it is selective for the adult skeletal muscle AChR over neuronal subtypes. Neurophysiological recordings from ex vivo mouse diaphragm preparations revealed that DC-98-LC74 elongates the endplate currents of wildtype (WT) adult but not fetal channel containing diaphragms. Single channel studies on chimeric channels of the adult and fetal receptor, and in saturating concentrations of choline, suggest that the PAM does not bind at either orthosteric site, but works by increasing the unliganded open probability via a mechanism that involves the ε M2-M3 loop. We also show that DC-98-LC74 increases the burst duration of multiple fast channel mutant AChR to WT levels, suggesting that positive allosteric modulation could be a therapeutic strategy for this difficult to treat subtype of congenital myasthenia. Promising preliminary data on aged sarcopenic mice also demonstrate that positive allosteric modulation of the muscle type AChR has potential benefits not only in myasthenia but also other neuromuscular disorders involving the neuromuscular junction.

Article Details

Volume / Issue Vol. 123, Issue 23
Published June 09, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (14)

R

Richard G. Webster

Nuffield Department of Clinical Neurosciences, University of Oxford

S

Setareh Alabaf

Nuffield Department of Clinical Neurosciences, University of Oxford

A

Anna Li

Nuffield Department of Clinical Neurosciences, University of Oxford

R

Rene Beerli

Novartis Biomedical Research

S

Sandra Siehler

Novartis Biomedical Research

P

Pierre-Eloi Imbert

Novartis Biomedical Research

L

Leonard Lee

Nuffield Department of Clinical Neurosciences, University of Oxford

J

Judith Cossins

Nuffield Department of Clinical Neurosciences, University of Oxford

M

Magdalena Koziczak-Holbro

Novartis Biomedical Research

L

Ludivine Flotte

Novartis Biomedical Research

L

Laurent Gaudet

Novartis Biomedical Research

N

Nicole Gerwin

Novartis Biomedical Research

D

David Beeson

Nuffield Department of Clinical Neurosciences, University of Oxford

Y

Yin Y. Dong